12 | MD Anderson Cancer Center Skip to Content
Top

BY Brette Peyton

MD Anderson Cancer Center welcomes Peter WT Pisters, M.D., as the 76-year-old institution’s fifth full-time president. Pisters was officially named to the post in September after being unanimously selected as the sole finalist by the UT System Board of Regents. The renowned cancer surgeon, researcher, professor and administrator previously served MD Anderson in faculty and leadership roles for more than 20 years. Most recently, he...

Peter WT Pisters

BY Lany Kimmons

In recognition of their contributions to basic, translational, and clinical research, six faculty members from MD Anderson Cancer Center have...

BY Clayton Boldt, Ph.D.

Elevated levels of chronic stress hormones, such as those produced by psychological distress, may promote resistance to drugs commonly used...

BY Clayton Boldt, Ph.D.

The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (PFS) in pre-menopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at MD Anderson.

The trial results, presented at the 2017 San Antonio Breast Cancer Symposium by...

BY Clayton Boldt, Ph.D.

In a randomized, Phase III trial led by MD Anderson researchers, the PARP inhibitor talazoparib extended progression-free survival (PFS) and...

BY Ron Gilmore

Researchers from MD Anderson Cancer Center presented their latest findings involving drug treatments for blood cancers at the American...